UNSPSC 51292923: Lofepramine hydrochloride

This classification denotes an antidepressant agent with the molecular formula C26H27ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z24K96F991, chemically known as 5h-dibenz(b,f)azepine, 5-(3-((p-chlorobenzoylmethyl)-n-methylamino)propyl)-, hydrochloride but more generally known as lofepramine hydrochloride, which bears US NIH Compound Identifier 33611. European Medicines Agency schedules Lofepramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02965MIG.

UNSPSC 51292923 Lofepramine hydrochloride is a Commodity code that captures pharmaceutical procurement activity across state and local jurisdictions, though recent activity in this code shows limited direct solicitations for the named substance itself. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The actual recent solicitations tagged to this code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through state cooperative purchasing frameworks, and direct-to-manufacturer prescription programs for health benefit administration. Vendors pursuing this code should expect to meet standard pharmaceutical compliance requirements including current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, FDA approval, and E-Verify employment eligibility confirmation, along with insurance minimums (workers' compensation, general liability in the $2 million to $5 million range, and professional liability coverage).

Recent activity is concentrated in Florida and Minnesota through cooperative purchasing mechanisms, with exploratory market intelligence activity in Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with electronic bid submission and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities including Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026; awarded vendors must work through AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co., with pricing weighted 75 percent in evaluation and a 3 percent administrative fee required. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information for a potential direct-to-manufacturer prescription program serving self-insured employer and state agency health plans, signaling downstream formal solicitation activity.